Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Nimes – page 54

1 423 clinical trials in Nimes, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Nimes at a glance
1 423
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 423 trials in Nimes

Open in trial search

Reducing abemaciclib, palbociclib and ribociclib after complete response in HER2‑negative metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Unicancer

HIV infection

Not yet recruiting

Study of Baricitinib and Sirolimus to Maintain HIV Infection Control After Antiretroviral Treatment Interruption in Adults

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Baricitinib
  • Sponsor:ANRS Maladies Infectieuses Emergentes

Hereditary ataxia+1

Not yet recruiting

Long‑term safety of intrathecal VO659 in participants with Huntington’s disease, spinocerebellar ataxia type 1 or type 3

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:VO659
  • Sponsor:Vico Therapeutics B.V.

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Acute myeloid leukaemia

Not yet recruiting

Study of quizartinib‑based drug combination on measurable residual disease in adults 18‑60 with acute myeloid leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azacitidine
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Hypersomnia

Not yet recruiting

Long‑term Safety and Tolerability Study of TAK‑360 in Adults with Narcolepsy or Idiopathic Hypersomnia

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

C3 glomerulopathy

Not yet recruiting

Pegcetacoplan to Prevent Recurrence of C3 Glomerulopathy or Primary Immune‑Complex MPGN in Adolescent and Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Epilepsy

Not yet recruiting

Efficacy of fluoxetine added to standard anti‑seizure therapy in children aged 8 years and older with drug‑resistant complex and rare epilepsy

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Fluoxetine
  • Sponsor:Assistance Publique Hopitaux De Marseille

Cardiac failure

Not yet recruiting

Effect of Continuing vs Stopping Dapagliflozin (with other drug combinations) on 30‑Day Cardiovascular Outcomes in Heart Failure Patients Undergoing Cardiac Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Alcoholic liver disease

Not yet recruiting

Safety and Efficacy of Efimosfermin Alfa vs Placebo in Adults with Alcohol-Related Liver Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Nimes

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Innovative trials focusing on cardiovascular conditions and metabolic disorders, examining new therapeutic approaches for heart and diabetes-related complications.

  • Atrial Fibrillation & Acute Coronary Syndrome Management
  • Type 2 Diabetes Cardiovascular Prevention
  • Chronic Kidney Disease Treatment

Studies evaluating novel drug combinations and monitoring strategies to improve patient outcomes.

02 Oncology Studies

Advanced research in cancer treatment, with particular focus on innovative therapies for various types of cancer.

  • Multiple Myeloma Therapy
  • Prostate Cancer Diagnostics
  • Triple Negative Breast Cancer Treatment

Trials exploring new treatment combinations and diagnostic approaches for better patient care.

03 Neurological Disorders

Comprehensive research into multiple sclerosis and other neurological conditions, testing innovative treatment approaches.

  • Progressive Multiple Sclerosis Therapies
  • Essential Tremor Treatment
  • Diabetic Peripheral Neuropathy

Focus on developing targeted therapies for various neurological conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.